UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 239

Sortiert nach

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

Blood, 2014-06, Vol.123 (23), p.3664-3671

2014

Link zum Volltext

Verfügbarkeit prüfen

What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?

Leukemia, 2024-01, Vol.38 (1), p.207-209

2024

Link zum Volltext

Verfügbarkeit prüfen

Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight

American journal of hematology, 2013-10, Vol.88 (10), p.906-909

2013

Link zum Volltext

Verfügbarkeit prüfen

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Blood, 2014-02, Vol.123 (9), p.1353-1360

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of growth factors compared to other therapies for low‐risk myelodysplastic syndromes

British journal of haematology, 2007-04, Vol.137 (2), p.125-132

2007

Link zum Volltext

Verfügbarkeit prüfen

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

Blood, 2009-01, Vol.113 (1), p.28-36

2009

Link zum Volltext

Verfügbarkeit prüfen

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

Blood, 2013-12, Vol.122 (24), p.3863-3870

2013

Link zum Volltext

Verfügbarkeit prüfen

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

Blood, 2013-09, Vol.122 (11), p.1974-1982

2013

Link zum Volltext

Verfügbarkeit prüfen

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Blood, 2013-05, Vol.121 (18), p.3703-3708

2013

Link zum Volltext

Verfügbarkeit prüfen

Advances in Acute Myeloid Leukemia Genomics, where do we stand in 2018?

Acta medica academica, 2019-04, Vol.48 (1), p.35

2019

Link zum Volltext

Verfügbarkeit prüfen

Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring

Journal of oncology pharmacy practice, 2022-06, p.10781552221104422

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

Cancer, 2011-03, Vol.117 (6), p.1253-1261

2011

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia

Leukemia & lymphoma, 2016-04, Vol.57 (4), p.803-811

2016

Link zum Volltext

Verfügbarkeit prüfen

Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation

Blood advances, 2019-09, Vol.3 (18), p.2732-2737

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience

Clinical lymphoma, myeloma and leukemia, 2018-01, Vol.18 (1), p.e95-e102

2018

Link zum Volltext

Verfügbarkeit prüfen

Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non‐Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide

British journal of haematology, 2010-01, Vol.148 (2), p.226-234

2010

Link zum Volltext

Verfügbarkeit prüfen

Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia

Leukemia research, 2008-03, Vol.32 (3), p.413-420

2008

Link zum Volltext

Verfügbarkeit prüfen

A Decision analysis to determine the appropriate treatment for low‐risk myelodysplastic syndromes

Cancer, 2007-03, Vol.109 (6), p.1125-1132

2007

Link zum Volltext

Verfügbarkeit prüfen

Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research

Biology of blood and marrow transplantation, 2014-01, Vol.20 (1), p.89-97

2014

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Biology of blood and marrow transplantation, 2020-02, Vol.26 (2), p.262-271

2020

Link zum Volltext

Verfügbarkeit prüfen

High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma

Leukemia & lymphoma, 2009-01, Vol.50 (10), p.1625-1631

2009

Link zum Volltext

Verfügbarkeit prüfen

White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia

Leukemia & lymphoma, 2007-01, Vol.48 (8), p.1561-1568

2007

Link zum Volltext

Verfügbarkeit prüfen

Impact of Obesity on Graft-Versus-Host Disease and Transplant Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Hematologic Malignancies

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S274-S275

2024

Link zum Volltext

Verfügbarkeit prüfen

Reducing Unplanned Medical Oncology Readmissions by Improving Outpatient Care Transitions: A Process Improvement Project at the Cleveland Clinic

Journal of oncology practice, 2016-05, Vol.12 (5), p.e594

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 239

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(232)

Publikationsform

Artikel
(238)
Berichte
(1)

Sprache

Englisch
(239)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(52)
Humans
(50)
Hematology
(40)
Middle Aged
(39)
Adult
(38)
Female
(36)
Hematology, Oncology And Palliative Medicine
(35)
Male
(34)
Aged
(29)
Oncology
(26)
Treatment Outcome
(20)
Immunology
(16)
Survival Analysis
(16)
Transplantation
(16)
Adolescent
(15)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Prognosis
(13)
Young Adult
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?

Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Efficacy of growth factors compared to other therapies for low‐risk myelodysplastic syndromes

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Advances in Acute Myeloid Leukemia Genomics, where do we stand in 2018?

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia

Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience

Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non‐Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide

Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia

A Decision analysis to determine the appropriate treatment for low‐risk myelodysplastic syndromes

Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research

Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma

White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia

Impact of Obesity on Graft-Versus-Host Disease and Transplant Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Hematologic Malignancies

Reducing Unplanned Medical Oncology Readmissions by Improving Outpatient Care Transitions: A Process Improvement Project at the Cleveland Clinic

Suchergebnisse filtern